Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 07, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically detailing transactions involving employee trusts and benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance disclosures regarding share ownership rather than financial performance.
Material Changes
The following material changes in directors' interests were reported:
- February 04, 2005: Abacus (GSK) Trustees Limited transferred 25,892 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- February 04, 2005: The Administrators of the SmithKline Beecham Employee Benefit Trust sold 2,087 Ordinary Shares on behalf of a participant in the SmithKline Beecham Bonus Investment Plan at a price of £11.882 per share.
- February 04, 2005: The same Trust transferred 3,012 Ordinary Shares to a participant in the SmithKline Beecham Bonus Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe are interested in shares held in the GSK Trust, while Director John Coombe is interested in shares held in the SmithKline Beecham Employee Benefit Trust, in the same capacity as other eligible employees.
Key Facts for Investor Verification
- Verify the total number of shares transferred or sold under the SmithKline Beecham Employee Share Option Plan 1991 and Bonus Investment Plan.
- Confirm the specific share price of £11.882 per share for the transaction on February 04, 2005.
- Review the full list of directors with interests in the GSK Trust and the SmithKline Beecham Employee Benefit Trust.
- Note that this filing does not contain financial results; refer to the company's Form 20-F for comprehensive financial data.